Despite Campaign Rhetoric, Trump Mostly Silent on Vaccine Policy

On the campaign trail, President Donald Trump met with prominent vaccine skeptics and ranted about the debunked theory that vaccines cause autism. But as the administration approaches its 100-day mark, the White House has given few indications about the direction of its vaccine policy.

That vacuum has left experts drawing their own conclusions, fueling the hopes of vaccine skeptics and the fears of advocates.

Changing vaccination and immunization policies appears to be a low priority for the administration. Trump hasn’t named his pick to lead the Centers for Disease Control and Prevention, which sets the childhood immunization schedule, and his first budget blueprint didn’t include details on vaccination funding.

For now, the CDC continues to promote immunizations as it did under the Obama administration.

The CDC “is working as part of the new administration to protect and advance the health of Americans through immunizations,” spokeswoman Kristen Nordlund said in an email.

Despite Trump’s inaction, anti-vaccine activists feel emboldened. Vaccine skeptics held a rally in Washington last month, when they also lobbied lawmakers on Capitol Hill.

Andrew Wakefield, the author of a since-discredited study linking vaccines to autism who met with Trump during the 2016 campaign, remains optimistic that the White House will act on his cause, though he said he hasn’t had contact with Trump since their meeting last summer.

“I truly hope that President Trump will follow through on this,” Wakefield said in a phone interview.

The uptick in anti-vaccine activism worries public health advocates, who fear Trump’s skepticism could affect immunization rates. Trump has said he doesn’t oppose vaccinations altogether, but also suggested that administering them over a period of time would lead to lower rates of autism.

There have already been 28 reported cases of measles this year, as of March 25, putting 2017 on pace to exceed the 70 cases from last year. While the United States declared the disease eradicated in 2000, its return could stem from states such as California where there is growing skepticism of vaccines.

“We cured polio, we had eradicated measles, we had eradicated mumps,” Kevin Campbell, a physician and health care consultant, said in a phone interview. “Now these things are reoccurring, and I’m concerned when the commander-in-chief is kind of waffling on these issues that it will help these unsubstantiated movements continue to grow.”

The White House hasn’t ruled out forming a special commission to investigate vaccine safety, though administration officials have rejected claims by vaccine skeptic Robert F. Kennedy Jr. that he would lead such a panel. Kennedy, who met with Trump during the transition, was unavailable for comment.

The White House has no announcements to make about vaccine policies at this time, according to a spokesman who noted that Trump has discussed science related to vaccine safety with drug makers and National Institutes of Health Director Francis Collins.

So far, the people Trump has tapped to lead federal health agencies reject the link between vaccines and autism.

Scott Gottlieb, Trump’s pick to head the Food and Drug Administration, which approves vaccines, has won praise from vaccine advocates for his efforts to counter the theory that vaccines cause autism. Some are also encouraged by Trump’s secretary of health and human services: Tom Price, a physician.

“To have someone who understands the science, who supports the science and uses the science to make decisions is what we want,” said L.J. Tan, chief strategy officer at the vaccine advocacy group Immunization Action Coalition.

Trump’s funding for the CDC’s 317 program, which funds vital immunization infrastructure nationwide, may provide more insight on his position. The program receives about $600 million annually, and advocates are pressing Congress to at least maintain existing levels.

“It’s about as low as it can go,” Tan said.

The White House is expected to send its final budget proposal to Congress in May. Complicating matters is the fact that about 45 percent of the program’s funding comes from the Prevention and Public Health Fund in the Affordable Care Act, which Republicans in Congress are trying to repeal.


Health Brief: GOP Senators Ask CBO to Fast-Track ACA Overhaul Review

Senate Republican leaders have asked the Congressional Budget Office to fast-track consideration of a plan from Sens. Lindsey Graham (R-S.C.) and Bill Cassidy (R-La.) to overhaul the Affordable Care Act. The CBO is reportedly in the process of analyzing the cost and coverage impact of the plan, as Republicans face pressure to make one last attempt at undoing the ACA before GOP senators’ ability to pass legislation with a simple majority expires on Sept. 30.

Health Brief: Week in Review & What’s Ahead

HELP Committee Chairman Lamar Alexander (R-Tenn.) hopes to reach a deal with Democrats on a plan to shore up the ACA exchanges early this week. A final agreement, if reached, is likely to extend key insurer payments, known as cost-sharing reductions, and include reforms to make it easier for states to establish reinsurance programs. Some Republicans are also pushing to give states more flexibility over required benefits in Obamacare plans, a proposal that is controversial with Democrats.

Health Brief: Some Moderate House Democrats Seek ACA Stabilization

While progressives this week rallied behind Sen. Bernie Sanders’ (I-Vt.) single-payer health care bill, a group of moderate House Democrats in the New Democrat Coalition aligned themselves with the Senate Health, Education, Labor and Pensions Committee’s bipartisan push to stabilize the Affordable Care Act exchanges, which Committee Chairman Lamar Alexander (R-Tenn.) aims to reach a final deal on by early next week.

Health Brief: Deal Reached to Extend CHIP Funding

Senate Finance Committee leaders reached a deal on a five-year reauthorization of the Children’s Health Insurance Program, in a win for children’s health advocates who are seeking longer-term funding certainty for the program, which will expire at the end of the month without congressional action. The deal also gradually phases out the enhanced federal share of funding for state CHIP programs, which was increased under the Affordable Care Act by 23 percentage points.

Health Brief: Some Navigators Shut Down Ahead of ACA Enrollment Period

Several navigator organizations, including one that received the largest federal grant for Obamacare enrollment activities in 2016, are suspending operations ahead of the 2018 open enrollment season because they haven’t received contracts for funding from the Department of Health and Human Services, which could cause enrollment to plummet. The Trump administration announced plans last month to cut funding for navigator groups by about 40 percent, but health officials haven’t said whether the grants would end altogether.

Health Brief: Teva Names New CEO

H. Lundbeck A/S’s Kaare Schultz was named as Teva Pharmaceutical Industries Ltd.’s new chief executive officer, ending a seven-month search by the world’s largest generic drug maker to find a new leader. Schultz could face pressure to split the company into two businesses, one focusing on patented specialty drugs and the other on cheap copycat medicines

Health Brief: Week in Review & What’s Ahead

HELP Committee Chairman Alexander hopes to reach bipartisan consensus on a bill to shore up the ACA exchanges by the end of the week. The committee is set to hold two final hearings as members try to resolve two issues: the duration of funding for insurer payments known as cost-sharing reductions and the best way to approach reinsurance.

Load More